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Abstract
Purpose—To evaluate the association between postpartum hormonal contraceptive use and 
postpartum depression.
Materials and methods—We searched the literature through March 2018 on the association 
between postpartum hormonal contraception use and incident postpartum depression. We used the 
United States Preventive Services Task Force framework to assess study quality.
Results—Of 167 articles identified, four met inclusion criteria. Two studies found no differences 
in rates of postpartum depression between women using postpartum depot medroxyprogesterone 
and those not using hormonal contraception; however, a study of women receiving injectable 
norethisterone enanthate immediately postpartum found a 2–3-fold increased risk of depression at 
six weeks, though not at three months. One study compared combined hormonal contraception, 
progestin-only pills (POPs), etonogestrel implants and levonorgestrel intrauterine devices (LNG-
IUDs) with no hormonal contraception, and found a 35–44% decreased risk of postpartum 
depression with POPs and LNG-IUDs, a small increased risk of postpartum antidepressant use 
among women using the etonogestrel implant and vaginal ring, and a decreased risk of 
antidepressant use with POPs.
Conclusions—Limited evidence found no consistent associations between hormonal 
contraceptive use and incidence of postpartum depression. Future research would be strengthened 
by using validated diagnostic measures, careful consideration of confounders, and ensuring 
adequate follow-up time.
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Introduction
Perinatal depression is defined as a major depressive episode in the peripartum time period, 
including during pregnancy and in twelve months following delivery. It affects an estimated 
12% of women globally [1], with peaks in incidence at 2 months and 6 months following 
delivery [2]. The strict diagnosis of postpartum depression is isolated to the time period of 
four weeks immediately postpartum [3]; however research and clinical guidelines generally 
consider the time when women are at risk for postpartum depression to range from delivery 
through three to twelve months postpartum [1, 4, 5]. Risk factors for postpartum depression 
include depression during or prior to pregnancy, life stress, traumatic or complicated birth 
experiences, and breastfeeding difficulties [4]. There are multiple options for treating 
postpartum depression, including different types of psychotherapy and antidepressant 
medications [6]. Uncontrolled postpartum depression can have negative impacts on the 
woman, her infant, and their families, including poor bonding, impaired infant development, 
and, rarely, suicide or infanticide [6]. Professional organizations, including the American 
College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and 
Clinical Excellence (NICE), and the World Health Organization (WHO), recommend that all 
women should be screened for postpartum depression during postpartum visits using a 
validated screening tool, such as the Edinburgh Postnatal Depression Scale, the Patient 
Health Questionnaire 9 or the Beck Depression Inventory [4, 5, 7].
Postpartum contraception facilitates optimal birth spacing, which improves maternal and 
pediatric outcomes [8]. Short interpregnancy intervals are associated with negative birth and 
infant outcomes, including preterm birth, low birthweight and infants born small for 
gestational age, and increased risk for uterine rupture for women attempting a trial of labor 
following a cesarean section [9]. Postpartum contraception helps women control the timing 
of subsequent pregnancies to best meet their and their families’ needs. ACOG, NICE and 
WHO also recommend that women receive contraceptive counseling and any desired 
contraceptive services during the postpartum time period [5, 7, 8]. Both the WHO and 
Centers for Disease Control and Prevention provide recommendations on the safety of 
initiating specific hormonal contraceptive methods in the postpartum period [10, 11]. Both 
the WHO and U. S. Medical Eligibility Criteria for Contraceptive Use recommendations 
consider progestin-only contraceptive methods to be generally safe for use any time in the 
postpartum period, while safe initiation of combined hormonal contraceptives may depend 
on the amount of time since delivery, presence of risk factors for venous thromboembolism, 
and breastfeeding status [10, 11].
Several studies have examined the influence of sex hormones and hormonal contraception 
on depressive symptoms in both healthy women and women with mental health diagnoses, 
based on hypotheses that exogenous estrogens and progestins influence mood-related 
neurotransmitters. However, results from these studies have been inconsistent and no clear 
conclusions have been reached [12, 13, 14, 15, 16]. Less work on this issue has been done 
among postpartum women [15], who may be at greater risk for depression due to their 
postpartum status [1]. Hormone fluctuations unique to the postpartum period, coupled with 
changes such as sleep deprivation, make this a distinct time period that warrants independent 
investigation. A recent analysis of adverse drug events reported to the US Food and Drug 
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Administration found elevated reporting odds ratios for postpartum depression with the use 
of certain hormonal contraceptives compared with the use of other drugs, and the authors 
concluded that this may indicate a possible “signal” that postpartum depression is more 
likely to be reported with the use of hormonal contraception [17]. The clinical relevance of 
these findings is unclear without further study. To better characterize the influence of 
hormonal contraception use during the postpartum period on the risk for subsequent 
identification of postpartum depression, this systematic review evaluated the published 
literature on the association between hormonal contraceptive use in the postpartum period 
and the incidence of postpartum depression. Specifically, we examined the research 
question: among postpartum women, do those using a hormonal contraceptive experience 
different rates of postpartum depression compared with those not using a hormonal 
contraceptive?
Materials and methods
We followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines in reporting this systematic review [18]. We developed a brief protocol 
to investigate our research question, including pre-specified inclusion criteria, search 
strategy and terms, and plan for assessing study quality, including risk of bias.
With the assistance of a librarian, we searched Medline, Embase, CINAHL, PsychINFO, the 
Cochrane Library, and Clinicaltrials.gov for studies involving any form of hormonal 
contraception (combined hormonal contraceptives, progestin-only pills, injectable 
contraceptives, contraceptive implants and LNG-IUDs) and postpartum depression (see 
supplemental material for the specific search terms) from database inception through March 
2018. We did not apply any language or publication date restrictions.
The first author conducted the initial study selection by reviewing titles and abstracts to 
determine which articles required full text review, and this was confirmed by the last author. 
Both authors then independently conducted the full text review to identify articles that met 
inclusion criteria. Disagreements were resolved by discussion and consensus. For each study 
that met inclusion criteria, data were extracted by the first author on: study design, location, 
timeframe of data collection, follow-up, study population, comparison group, outcome(s), 
results, and funding source, and the data extraction tables were reviewed by the last author.
We included studies of original research in the form of randomized controlled trials (RCTs), 
cohort and case-control studies of postpartum women using a specific form of hormonal 
contraception compared with postpartum women not using hormonal contraception. The 
exposure of interest was the method of hormonal contraception used postpartum, which 
included combined hormonal contraceptives (pills, patch, and ring), progestin-only pills, 
injectable contraceptives, contraceptive implants and levonorgestrel-containing intrauterine 
devices (LNG-IUDs). The comparison was no hormonal contraceptive use in the study 
period, which included women using non-hormonal methods such as sterilization, copper 
IUD, or barrier methods, as well as women using no contraception. The outcome of interest 
was the development of depression within the postpartum period, as identified by any 
clinical diagnosis of depression by a health care provider within the 12 months postpartum 
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or a score above a threshold for depression on a validated depression scale. Clinical 
diagnosis could be self-reported or assessed through the clinical record. Secondary outcomes 
included antidepressant use, suicidal ideation or suicide attempt, and hospitalization for 
depression. We excluded studies that included women with a pre-existing diagnosis of 
depression or who were receiving treatment for depression prior to or during pregnancy, as 
we were interested in examining the association between hormonal contraceptive use and 
incidence of depression in the postpartum period, rather than whether hormonal 
contraceptive use might impact existing mood disorders in the postpartum period.
To assess the overall quality of the evidence, we followed the framework developed by the 
United States Preventive Services Task Force [19], and assigned a quality rating (good, fair, 
poor) based on the evidence provided for each outcome by study. We assessed the risk of 
bias for individual outcomes within studies, study precision, and external validity. 
Components included in the risk of bias assessment differed by study design. For all studies, 
we assessed selection bias, reporting bias and performance bias. For RCTs, we also assessed 
detection bias, attrition bias and any other sources of biases relevant to the study. For cohort 
and case-control studies, we also assessed information bias and confounding. The quality of 
each study outcome was graded independently by each author and differences were resolved 
through discussion. Because of the heterogeneity of exposures and outcomes, we did not 
calculate summary measures of association.
Results
Our search identified 167 unique articles that were then screened by their title and abstract 
(Figure 1). The full texts of 21 articles were reviewed, and four met the inclusion criteria 
(Tables 1 and 2). The majority of articles were excluded because they did not address our 
question or were not primary studies. One was excluded because it did not use a validated 
scale to assess depression [20]. Another was excluded because it included both users of no 
contraception and users of combined oral contraceptives (COCs) as one comparison group 
[21]. In three of the included studies, women using injectable forms of contraception (either 
depot medroxyprogesterone acetate [DMPA] or norethisterone acetate [NET-EN]) were 
recruited from teaching hospitals or outpatient obstetric clinics in South Africa or the United 
States. The included fourth study used a large claims database of military personnel in the 
United States to examine a wide range of hormonal contraceptive types. All four included 
studies examined incidence of depression in the postpartum period and one study [22] also 
examined use of antidepressant medications. We did not identify any studies that looked at 
hospitalization for depression, suicidal ideation or suicide attempts.
Depression
For the outcome of depression, two RCTs [23, 24] and two retrospective cohort studies [22, 
25] met inclusion criteria (Table 1). The studies included a total of 76,409 participants, with 
the majority (75,528) stemming from one study [22]. The remaining studies had sample 
sizes ranging from 180 to 247 participants. Two studies were conducted in the U.S. [22, 25], 
and the other two conducted in South Africa [23, 24]. One study assessed the risk of a 
diagnosis of depression in the postpartum period associated with various contraceptive 
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methods: COCs, the contraceptive vaginal ring, progestin-only pills, contraceptive implants, 
and LNG-IUDs [22]. Three studies examined the association of either depot 
medroxyprogesterone (DMPA) or injectable norethisterone enanthate (NET-EN) use in the 
postpartum period on scores on validated depression scales [23, 24, 25]. The comparison 
groups were generally women not using contraception or not using a hormonal method (e.g. 
using barriers, copper IUD or tubal ligation). Incidence of depression was assessed through 
diagnostic codes in one study [22] and through depression scales, including the Edinburgh 
Postnatal Depression Scale (EPDS) [25], EPDS and the Beck Depression Inventory (BDI-II) 
[24], and EPDS plus the Montgomery-Åsberg Depression Rating Scale (MADRS) [23] in 
the other three studies. Estimates of the overall incidence of depression in the study 
population varied, though tended to be lower in the study using diagnosis codes (Kaplan-
Meier estimate of 5.0%, over 12 months) [22] and was as high as 14.1% using a diagnostic 
cutoff for major depression on a depression scale at 6 weeks postpartum [25]. For the 
outcome of depression, two studies were graded as fair quality [22, 23] and two were poor 
quality [24, 25].
Combined hormonal methods—Only one study examined combined hormonal 
methods, including two formulations of COCs and the vaginal ring [22]. This large 
retrospective cohort study of fair quality used claims data within the U.S. military health 
insurance program to compare women using hormonal contraception with those not using a 
hormonal method through 12 months postpartum, with mean follow-up of 8.9 months 
postpartum. Contraceptive use was assessed through pharmacy codes and incidence of 
depression through diagnostic codes. Women with any diagnostic codes for depression or 
antidepressant prescription in the 24 months prior to delivery were excluded from the 
analysis. Over 75,000 women were included in the analysis, and 5,797 of them used a 
combined hormonal method while 44,022 used no hormonal contraception. After adjustment 
for age, beneficiary category (e.g. military retiree, active duty service member, or family 
member) and rank of insurance sponsor (as proxies for socioeconomic status), no significant 
associations were observed between the use of ethinyl estradiol/norgestimate pills (adjust 
hazard ratio [aHR] 0.89, 95% confidence interval [CI] 0.70–1.14), ethinyl estradiol/
norethindrone pills (aHR 0.82, 95% CI 0.59–1.12), or the vaginal ring (aHR 1.09, 95% CI 
0.80–1.50) and diagnosis of depression.
Injectables—Three studies examined the association between the use of injectable 
progestin contraception and postpartum depression. One poor quality RCT randomized 242 
women in South Africa to immediate (within 48 hours of delivery) postpartum use of DMPA 
or copper IUD. Incidence of depression was measured through use of EPDS and BDI-II 
scores using validated thresholds for major and minor depression at 1 and 3 months 
postpartum [24]. While mean scores on both scales tended to be higher in DMPA users 
compared with copper IUD users, there were no significant differences in the proportions of 
women reaching the thresholds for major or minor depression using either scale at one or 
three months postpartum. A poor quality, retrospective cohort study of medical records from 
247 women with postpartum visits at an outpatient clinic in the United States found no 
statistically significant association between the use of immediate (prior to hospital 
discharge) postpartum DMPA and major depression on the EPDS at the 6-week postpartum 
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visit compared with women not using birth control or who had a tubal ligation (p=0.88) [24]. 
A fair quality, placebo-controlled RCT of intramuscular NET-EN enrolled 180 postpartum 
women from a tertiary care hospital in South Africa. A single dose of NET-EN administered 
within 48 hours of delivery was significantly associated with scoring above the threshold for 
major or minor depression on the EPDS (relative risk (RR) = 3.04, p=0.002) and major or 
minor depression on MADRS (RR=2.56, p=0.008), but not major depression alone on 
MADRS (RR=2.13, p=0.158) at 6 weeks postpartum. This association was not observed at 3 
months (major or minor depression on EDPS, RR=1.20, p=0.573; major depression on 
MADRS, RR 1.09, p=0.895; major or minor depression on MADRS, RR 1.03, p=0.930) 
[23].
Implant—One fair quality study assessed the association between progestin contraceptive 
implants and postpartum depression. The retrospective cohort study of U.S. military health 
insurance claims data included 2,730 implant users and 44,022 women using no hormonal 
contraception, and found no association between etonogestrel (ETG) implant use and 
diagnosis of postpartum depression during the 12 months after delivery (aHR 1.01, 95% CI 
0.83–1.22) [22].
LNG-IUD—The only study to look at the LNG-IUD was the large retrospective cohort study 
of fair quality that used military health insurance claims data. Investigators reported a 
reduced risk of depression diagnosis among 3,096 LNG-IUD users compared with 44,022 
women not using hormonal contraception (aHR 0.65, 95% CI 0.52–0.82) [22].
Anti-depressant use
In addition to a diagnosis of depression, the claims data analysis [22] also looked at 
antidepressant use as measured by filled prescriptions of any antidepressant during 12 
months after delivery [26]. Overall, antidepressant were prescribed at an estimate rate of 
7.8% (95% CI 7.6–8.0) during the postpartum period. For this outcome, we graded this 
study to be poor quality (Table 2). Investigators reported an elevated risk of antidepressant 
use in the postpartum period among postpartum women using the vaginal ring (aHR 1.45, 
95% CI 1.16–1.8) and the ETG implant (aHR 1.22, 95% CI 1.06–1.41) compared with 
women not using hormonal contraception. This study also found a reduced risk of 
antidepressant use among women who used progestin-only pills as compared to women not 
using hormonal contraception (aHR 0.58, 95% CI 0.52–0.64). There were no significant 
associations between the use of ethinyl estradiol/norgestimate pills (aHR 1.02, 95% CI 0.85–
1.22), ethinyl estradiol/norethindrone pills (aHR 0.88, 95% CI 0.69–1.13) or LNG-IUDs 
(aHR 1.01, 95% CI 0.87–1.18) and antidepressants.
Discussion
We identified four studies that examined the risk of postpartum depression among women 
using hormonal contraception in the postpartum time period. Of the four studies, three 
studies looked only at injectable contraceptives. These three studies used cutoffs on a 
validated scale to identify women with postpartum depression. One RCT and one 
retrospective cohort study found no differences in the rates of postpartum depression 
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between women using postpartum DMPA and those not using a hormonal contraceptive [24, 
25]; however, an older RCT of women receiving a single dose of immediate postpartum 
NET-EN found a 2–3-fold increased risk of depression at six-weeks postpartum on two 
different depression scales, though differences were not observed at three months 
postpartum [23]. Only one study looked at the use of COCs, the contraceptive vaginal ring, 
progestin-only pills, the ETG implant and the LNG-IUD within the 12 months postpartum, 
and found a decreased risk of receiving a diagnosis of postpartum depression with progestin-
only pills and the LNG-IUD, and no association with the other methods [22]. This same 
study found an increased risk of the postpartum use of antidepressants among women using 
the ETG implant and the vaginal ring, a decreased risk of postpartum antidepressant use 
among women using the progestin-only pill, and no association with those using the LNG-
IUD or combined oral contraceptives.
Outside of the postpartum period, the association between hormonal contraception use and 
incidence of depression is also unclear. Three reviews were unable to draw firm conclusions 
from the evidence they evaluated [14, 15, 27]. Three recent large cohort studies found 
conflicting results, with two related studies finding an increased risk of depression and 
suicide among users of hormonal contraception [28, 29] and another finding decreased levels 
of depressive symptoms among women using hormonal contraception [30]. Among women 
who have depressive mood disorders, the very limited available evidence does not suggest 
worse outcomes for those who use hormonal contraception [13, 15].
The available evidence to answer our question is limited in both quantity and quality. The 
majority of this evidence comes from a single, large study of claims data among military 
personnel in the United States, and the remaining studies only provide data on injectable 
contraceptives. Of the four articles that met our inclusion criteria, we judged them to be 
either fair [22, 23] or poor [24, 25] quality. Of the cohort studies, one failed to adjust for any 
confounders [25] and the other missed some key potential confounders, including smoking 
status, pregnancy complications, breastfeeding status or difficulties, and prior history of 
postpartum depression [22]. Three of the studies followed women only to three months or 
less postpartum [23, 24, 25], which may not be enough time to observe the outcome. One 
RCT had a response rate of 25%, which raises concerns of significant selection bias and 
generalizability [24]. The external validity was also limited for three of the studies. The RCT 
that had a very low response rate was based in a teaching hospital in South Africa [23], 
which may limit the representativeness of their sample. The other RCT was also based in 
South Africa and had a low response rate (42%) and a very high rate of unplanned 
pregnancies (77%) [24]. One of the cohort studies used the U.S. military health insurance 
database [22], and while it likely represented a diverse cohort of families, it is unclear if 
findings from a military-involved population are generalizable to the general population. 
When considering the overall body of evidence, even though we only included studies using 
validated scales for postpartum depression, there was still significant heterogeneity in the 
scale used, the timing of the assessment, as well as the thresholds used for diagnosis within 
the same scale. All of these differences make it difficult to make comparisons across studies.
Additionally, the use of antidepressant prescription as a proxy for depression diagnosis or 
symptoms is questionable, especially within a military cohort that may have higher rates of 
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comorbid psychiatric conditions, such as acute- and post-traumatic stress disorders, anxiety 
disorders and chronic pain, which may also be treated with antidepressants. Even in general 
primary care settings, anywhere from one-third to nearly one-half of antidepressant 
prescriptions are for off-label use [31, 32]. These discrepancies may result in differential 
misclassification, for example, if those who are interested in using a hormonal contraceptive 
may also be more open to using antidepressants for off-label reasons or as treatment for a 
psychiatric condition, over non-pharmacologic alternatives.
The use of postpartum contraception remains an important intervention to reduce rapid 
repeat pregnancy and improve maternal and pediatric outcomes, while postpartum 
depression continues to be of significant public health concern. The studies included in this 
review also demonstrated relatively high rates of postpartum depression (5–14%), whether 
identified through diagnosis codes used in billing or through using cutoffs for major 
depression based on validated scales. Because we excluded studies of women with pre-
existing mood disorders, these estimates likely underestimate the true burden of depression 
for all women in the postpartum period. This highlights the importance of patient education 
and routine screening for postpartum depression. Based on limited available evidence from 
two cohort studies and two RCTs of fair to poor quality, there is not a clear association 
between any specific forms of hormonal contraception and the development of postpartum 
depression; however, these findings should be interpreted with caution, given the paucity of 
high quality research. The lack of high quality studies on this topic precludes clear clinical 
implications based on the evidence. Further research including well-designed studies with 
sufficient follow-up (e.g. six months to one year), using a validated scale such as the EPDS 
or diagnoses based on billing codes from provider visits to evaluate the outcome of 
postpartum depression would advance the field. This information could better inform 
conversations between women and their providers in how to best choose a method of 
postpartum contraception, including in the immediate and early postpartum periods. 
Currently, women’s health care providers can use evidence-based recommendations [10, 11] 
to provide patient-centered care in helping postpartum women choose and initiate 
contraception that is best suited to their needs and help manage side effects should they 
occur.
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Figure 1. 
PRISMA flowchart
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ste
d h
aza
rd 
rat
io.
 C
I =
 95
% 
co
nfi
de
nc
e 
in
te
rv
al
. I
CD
-9
 =
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
ise
as
e,
 N
in
th
 
re
v
isi
on
. N
O
S=
no
t o
th
er
w
ise
 sp
ec
ifi
ed
. R
CT
 =
 ra
nd
om
iz
ed
 c
on
tro
lle
d 
tri
al
. D
M
PA
 =
 d
ep
ot
 m
ed
ro
xy
pr
og
es
te
ro
ne
 a
ce
ta
te
. C
u-
IU
D
 =
 c
op
pe
r i
nt
ra
ut
er
in
e 
de
v
ic
e.
 N
ET
-
EN
=n
or
et
hi
ste
ro
ne
 e
th
an
at
e.
 R
R=
 
re
la
tiv
e 
ris
k.
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Ta
bl
e 
2.
St
ud
y 
of
 w
o
m
en
 r
ec
ei
v
in
g 
an
 a
nt
id
ep
re
ss
an
t p
re
sc
rip
tio
n 
in
 th
e 
po
stp
ar
tu
m
 p
er
io
d.
Au
th
or
, 
ye
a
r,
 
su
pp
or
t, 
co
u
n
tr
y
St
ud
y 
de
sig
n,
 p
op
ul
at
io
n
C
on
tr
ac
ep
tiv
e 
u
se
O
ut
co
m
e
R
es
ul
ts
Qu
ali
ty,
 s
tr
en
gt
hs
, w
ea
kn
es
se
s
R
ob
er
ts,
 
20
17
, n
o 
fu
nd
in
g,
 
U
.S
.
R
et
ro
sp
ec
tiv
e 
co
ho
rt 
stu
dy
,
 
an
al
ys
is 
of
 d
at
a 
fro
m
 M
ili
ta
ry
 
H
ea
lth
 S
ys
te
m
 M
an
ag
em
en
t 
A
na
ly
sis
 a
nd
 R
ep
or
tin
g 
To
o
l.
75
,5
28
 w
o
m
en
 e
n
ro
lle
d 
po
stp
ar
tu
m
 a
nd
 fo
llo
w
ed
 fo
r 1
2 
m
o
n
th
s.
N
or
et
hi
nd
ro
ne
-o
nl
y 
pi
lls
 
(n=
19
,88
3)
LN
G
-IU
D
 (n
=3
,09
6)
ET
G
 im
pl
an
t (
n=
2,7
30
)
EE
/n
or
ge
sti
m
at
e 
pi
ll 
(n=
2,7
18
)
EE
/n
or
et
hi
nd
ro
ne
 p
ill
 
(n=
1,6
75
)
EE
/E
TG
 ri
ng
 (n
=1
,40
4)
N
o 
ho
rm
on
al
 
co
n
tr
ac
ep
tio
n 
(n=
44
,02
2)
A
nt
id
ep
re
ss
an
t u
se
 a
s 
id
en
tif
ie
d 
by
 p
ha
rm
ac
y 
re
co
rd
 o
f f
ill
ed
 
pr
es
cr
ip
tio
n 
of
 a
n 
an
tid
ep
re
ss
an
t d
ef
in
ed
 
u
sin
g 
th
e 
A
m
er
ic
an
 
H
os
pi
ta
l F
o
rm
u
la
ry
 
Se
rv
ic
e 
cl
as
sif
ic
at
io
n 
co
de
 2
81
60
4 
du
rin
g 
12
 
m
o
n
th
s a
fte
r d
el
iv
er
y.
 
Ex
cl
ud
ed
 tr
ic
yc
lic
 
an
tid
ep
re
ss
an
ts 
an
d 
se
ro
to
ni
n 
re
up
ta
ke
 
in
hi
bi
to
rs
 ty
pi
ca
lly
 
pr
es
cr
ib
ed
 fo
r s
m
ok
in
g 
ce
ss
at
io
n 
(B
up
rop
rio
n 
H
CL
 fo
rm
ul
at
ed
 a
s 
Zy
ba
n®
) o
r i
ns
om
nia
 
(T
ra
zo
do
ne
).
N
or
et
hi
nd
ro
ne
-o
nl
y 
pi
lls
a
H
R
 0
.5
8 
(0.
52
–0
.64
)
LN
G
-IU
D
aH
R
 1
.0
1 
(0.
87
–1
.18
)
ET
G
 im
pl
an
t
a
H
R
 1
.2
2 
(1.
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–1
.41
)
EE
/n
or
ge
sti
m
at
e 
pi
ll
aH
R
 1
.0
2 
(0.
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–1
.22
)
EE
/n
or
et
hi
nd
ro
ne
 p
ill
aH
R
 0
.8
8 
(0.
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–1
.13
)
EE
/E
TG
 ri
ng
a
H
R
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.4
5 
(1.
16
–1
.8)
Qu
ali
ty:
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(hi
gh
 ri
sk
 of
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as,
 go
od
 pr
ec
isi
on
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ir 
ex
te
rn
al
 
v
al
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)
St
re
ng
th
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La
rg
e 
co
ho
rt 
us
in
g 
cl
ai
m
s d
at
a 
w
ith
in
 a
 re
la
tiv
el
y 
cl
os
ed
 h
ea
lth
 c
ar
e 
sy
ste
m
, w
ith
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de
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at
e 
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llo
w
-u
p 
fo
r o
ut
co
m
e 
(12
 m
on
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). G
rou
ps
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n
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e 
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m
e 
so
ur
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op
ul
at
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n 
w
ith
 c
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sis
te
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us
io
n 
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d 
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us
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n 
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ite
ria
. E
xp
os
ur
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an
d 
o
u
tc
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e 
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se
ss
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 c
on
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te
nt
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ro
ug
ho
ut
 p
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ip
an
ts 
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in
g 
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r d
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gn
os
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 c
od
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. L
ik
el
y 
a 
di
v
er
se
 p
op
ul
at
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n 
(th
ou
gh
 no
 
da
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 p
re
se
nt
ed
), a
nd
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el
y 
ad
eq
ua
te
 p
ow
er
 g
iv
en
 la
rg
e 
sa
m
pl
e 
siz
e 
(th
ou
gh
 no
 po
w
er
 o
r 
ef
fe
ct
 si
ze
 c
al
cu
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tio
ns
 p
ro
v
id
ed
). 
Ex
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ud
ed
 p
rio
r d
ep
re
ss
io
n 
di
ag
no
sis
 o
r a
nt
id
ep
re
ss
an
t u
se
 
w
ith
in
 2
4 
m
on
th
s p
rio
r t
o 
de
liv
er
y.
W
ea
kn
es
se
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Si
gn
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nt
 p
ot
en
tia
l f
or
 m
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la
ss
ifi
ca
tio
n 
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o
u
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om
e.
 F
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le
d 
to
 a
dju
st 
for
 ke
y 
po
te
nt
ia
l c
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fo
un
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an
al
ys
is 
(e.
g. 
sm
ok
ing
, p
rio
r h
ist
ory
 of
 po
stp
art
um
 de
pre
ssi
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, 
bi
rth
 c
om
pl
ic
at
io
ns
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r b
re
as
tfe
ed
in
g 
pr
ob
le
m
s).
 M
ilit
ary
 co
ho
rt 
w
ith
 p
ot
en
tia
l f
or
 h
ig
he
r r
at
es
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f c
om
or
bi
d 
ps
yc
hi
at
ric
 
co
n
di
tio
ns
 (e
.g.
 po
st-
tra
um
ati
c s
tre
ss 
dis
ord
er)
. U
niq
ue
 
po
pu
la
tio
n 
w
ith
 p
ot
en
tia
lly
 li
m
ite
d 
ge
ne
ra
liz
ab
ili
ty
.
LN
G
-IU
D
 =
 le
v
o
n
o
rg
es
tre
l i
nt
ra
ut
er
in
e 
de
v
ic
e.
 E
TG
 =
 e
to
no
ge
str
el
. E
E 
= 
et
hi
ny
l e
str
ad
io
l. 
IC
D
-9
 =
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
ise
as
e,
 N
in
th
 re
v
isi
on
. N
O
S=
no
t o
th
er
w
ise
 sp
ec
ifi
ed
. a
H
R=
 a
dju
ste
d 
ha
za
rd
 ra
tio
. C
I =
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5%
 co
nf
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 in
te
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.
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